Last reviewed · How we verify
Anti-Thymocyte Globulins treatment
Anti-thymocyte globulin (ATG) depletes T lymphocytes by binding to T-cell antigens and triggering their destruction, thereby suppressing the adaptive immune response.
Anti-thymocyte globulin (ATG) depletes T lymphocytes by binding to T-cell antigens and triggering their destruction, thereby suppressing the adaptive immune response. Used for Prevention of acute organ rejection in allogeneic transplantation (renal, cardiac, hepatic), Treatment of aplastic anemia, Graft-versus-host disease (GVHD) prophylaxis and treatment.
At a glance
| Generic name | Anti-Thymocyte Globulins treatment |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | Polyclonal antithymocyte antibody |
| Target | T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
ATG is a polyclonal antibody preparation derived from immunized animals (typically rabbits or horses) that targets multiple antigens on the surface of T cells. Upon binding, it activates complement-mediated lysis and antibody-dependent cellular cytotoxicity, leading to rapid T-cell depletion. This profound immunosuppression is used to prevent graft rejection in transplantation and to treat T-cell mediated autoimmune conditions.
Approved indications
- Prevention of acute organ rejection in allogeneic transplantation (renal, cardiac, hepatic)
- Treatment of aplastic anemia
- Graft-versus-host disease (GVHD) prophylaxis and treatment
Common side effects
- Fever and chills
- Thrombocytopenia
- Leukopenia
- Serum sickness
- Infection (opportunistic)
- Anaphylaxis
- Lymphadenopathy
Key clinical trials
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation (PHASE2)
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders (PHASE2)
- TReatment for ImmUne Mediated PathopHysiology (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |